From : Tamar Gabunia <tgabunia@moh.gov.ge>
To : etikaradze@yahoo.de; Ekaterine Tikaradze <etikaradze@moh.gov.ge>
Subject : FW: Update on Pfizer/BioNTech
Received On : 23.02.2021 15:07
Attachments :

fyi

 

From: Rosie Grieves (Consultant) [mailto:rgrieves@gavi.org]
Sent: 22 February, 2021 21:32
To: Tamar Gabunia
Cc: Maia Nikoleishvili ; Natia Khmaladze ; Alexander Khvtisiashvili ; gkhalil@unicef.org; domentes@who.int; Santiago Cornejo ; Sam Muller ; Pascal Bijleveld ; Hannah Kettler (Consultant) ; Katherine Hudak ; Dorcas Noertoft ; Liu, Alvin HL ; Akande, Michelle ; Sousa, Patricia
Subject: Update on Pfizer/BioNTech

 

Dear Tamar, 

 

I am writing to share an update on the initial limited volume of the COVID-19 vaccine requiring ultra-cold chain produced by Pfizer/BioNTech. After several conversations with Pfizer over the last three weeks, we can now provide more information for your planning purposes.  Thank you for your patience as we have worked through these issues.

 

Key next steps are outlined in the letter attached. I will be in touch to arrange a meeting for later this week between Pfizer, Government of Georgia and Covax to discuss further.

 

Best wishes

 

Rosie

 

Rosie Grieves

Senior Manager Country Engagement 

Mobile: +44 7849 574189

Web: gavi.org

 

 

NOTICE: This email, including any attachments to it, may be confidential and does not create any binding contract on behalf of Gavi or its partners.

If this email was sent to you in error, please notify the send